2. Academic Validation
  3. Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38α Mitogen-Activated Protein Kinase Inhibitors

Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38α Mitogen-Activated Protein Kinase Inhibitors

  • J Med Chem. 2025 Aug 28;68(16):17378-17411. doi: 10.1021/acs.jmedchem.5c00933.
Svit Ferjančič Benetik 1,  Matic Proj 1,  Damijan Knez 1,  Urban Košak 1,  Anže Meden 1,  Katja Krajšek 1,  Anja Pišlar 1,  Selena Horvat 1,  Urban Švajger 2,  Nataša Tešić 2,  Lenka Pulkrabkova 3,  Ondrej Soukup 3,  Adam Skarka 4,  Rudolf Andrys 4,  Xavier Brazzolotto 5,  Alexandre Igert 5,  Florian Nachon 5,  Jose Dias 5,  Jan Detka 6,  Joanna Gdula-Argasińska 7,  Elżbieta Wyska 8,  Małgorzata Szafarz 8,  Aleksandra Manik 6,  Natalia Płachtij 6,  Kamil Musílek 3 4,  Kinga Sałat 6,  Aleš Obreza 1,  Stanislav Gobec 1
Affiliations

Affiliations

  • 1 Faculty of Pharmacy, Department of Pharmaceutical Chemistry, University of Ljubljana, 1000 Ljubljana, Slovenia.
  • 2 Department for Therapeutic Services, Blood Transfusion Center of Slovenia, 1000 Ljubljana, Slovenia.
  • 3 Biomedical Research Centre, University Hospital in Hradec Kralove, 500 05 Hradec Kralove, Czech Republic.
  • 4 Faculty of Science, Department of Chemistry, University of Hradec Kralove, 500 03 Hradec Kralove, Czech Republic.
  • 5 Département de Toxicologie et Risques Chimiques, Institut de Recherche Biomédicale des Armées, 91220 Paris, France.
  • 6 Department of Pharmacodynamics, Chair of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., 30-688 Krakow, Poland.
  • 7 Department of Radioligands, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., 30-688 Krakow, Poland.
  • 8 Department of Pharmacokinetics and Physical Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., 30-688 Kraków, Poland.
PMID: 40779804 DOI: 10.1021/acs.jmedchem.5c00933
Abstract

The currently approved drugs for the treatment of Alzheimer's disease (AD) fail to address its interconnected pathological processes. Inhibition of butyrylcholinesterase (BChE) and p38α mitogen-activated protein kinase (p38α MAPK) offers an innovative dual approach to mitigate two major drivers of neurodegeneration in AD: cholinergic deficit and neuroinflammation. Using structure-based drug design and a library of known p38α MAPK inhibitors, we developed first-in-class, selective dual BChE/p38α MAPK inhibitors with balanced activity against both targets. The X-ray crystal structures of the two most promising molecules bound to both Enzymes were solved. Those ligands effectively reduced the production of proinflammatory markers in vitro and ex vivo in phytohemagglutinin/lipopolysaccharide neuroinflammation models. Remarkably, these compounds also significantly improved cognition in scopolamine- and lipopolysaccharide-induced models of cognitive dysfunction in mice. Because our dual-acting inhibitors target both the symptoms and the underlying neuropathology, they offer an innovative and comprehensive strategy to combat AD.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z